Provided by Tiger Fintech (Singapore) Pte. Ltd.

BlackRock Virginia Municipal Bond Trust

10.39
-0.0874-0.83%
Post-market: 10.390.00000.00%16:04 EDT
Volume:3.15K
Turnover:32.98K
Market Cap:16.50M
PE:57.92
High:10.53
Open:10.38
Low:10.38
Close:10.48
Loading ...

BRIEF-BlackRock Announces Board Approvals Seeking To Deliver Significant Scale Benefits To Municipal CEF Shareholders

Reuters
·
09 Jun

BlackRock Announces Board Approvals Seeking to Deliver Significant Scale Benefits to Municipal Cef Shareholders

THOMSON REUTERS
·
09 Jun

BlackRock Virginia Municipal Bond Trust Announces Distribution Report for June 2025

Reuters
·
03 Jun

Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

THOMSON REUTERS
·
03 Jun

Press Release: Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

Dow Jones
·
03 Jun

BlackRock Virginia Municipal Bond Trust Files Initial Beneficial Ownership Statement for Stephen Thomas Minar, Vice President

Reuters
·
17 May

Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

THOMSON REUTERS
·
02 May

Press Release: Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

Dow Jones
·
02 May

Biohaven Ltd. Receives Buy Rating from Sarah Schram Due to Promising BHV-1300 Trial Results and Strong Pipeline

TIPRANKS
·
04 Mar

Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

THOMSON REUTERS
·
04 Mar

Press Release: Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

Dow Jones
·
04 Mar

Biohaven reports ‘positive’ data from study of BHV-1300

TIPRANKS
·
03 Mar

Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300

PR Newswire
·
03 Mar

Press Release: Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

Dow Jones
·
04 Feb

Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval

Benzinga
·
18 Dec 2024

Promising Pipeline Developments and BHV-1300 Efficacy Boost Biohaven Ltd.’s Buy Rating

TIPRANKS
·
17 Dec 2024

Biohaven Says BHV-1300 Achieves 'Deep Lowering' of Targeted IgG During Early-Stage Trial

MT Newswires Live
·
16 Dec 2024